BFRG

BFRG

NASDAQ

Bullfrog AI Holdings, Inc. Common Stock

1.2778

0.7695(151.39%)
Volume

396.9M

Market Cap

$13.55M

P/E Ratio

-1.40

EPS

$-0.63


Price Chart

Price Alerts

No price alerts set. Add an alert to get notified!

Notify when price goes above $120.00
Notify when price goes above $180.00
Notify when price goes below $180.00

Key Financial Ratios

P/E Ratio

-1.40

P/B Ratio

0.00

EPS

$-0.63

ROE

0.00%

Profit Margin

-5,569.61%

Operating Margin

-5,652.38%

Peer Comparison

Compare TSM with similar companies in the sector

Company Price Change % P/E Market Cap D/E
BFRI
Biofrontera Inc.
$0.77 -5.67% -0.85 $9.00M 0.59
BRTX
BioRestorative Therapies, Inc.
$0.27 -10.80% -0.17 $2.35M 0.00
COCP
Cocrystal Pharma, Inc.
$1.00 -2.91% -1.14 $10.25M 0.21
CODX
Co-Diagnostics, Inc.
$1.70 -2.86% -0.07 $1.90M 0.04
DWTX
Dogwood Therapeutics, Inc.
$1.85 -6.57% -0.09 $3.54M 0.00
EDSA
Edesa Biotech, Inc.
$5.29 -9.11% -5.40 $44.16M 0.00
EVGN
Evogene Ltd.
$0.73 -10.79% -0.81 $6.37M -26.80
IMRN
Immuron Limited
$0.76 -5.59% -1.65 $4.90M 0.00
SCNX
Scienture Holdings, Inc.
$0.24 -41.97% 0.00 $3.72M 0.00
TRAW
Traws Pharma, Inc.
$1.75 -0.57% -1.12 $8.34M 0.00

* Peer stocks are selected based on market capitalization and sector

Private Notes

Key Statistics

52 Week High

$2.20

52 Week Low

$0.43

Dividend

$0.00

Dividend Yield

0.00%

About Bullfrog AI Holdings, Inc. Common Stock

BullFrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. It offers bfLEAP, an AI/ML platform for the analysis of preclinical and/or clinical data. The company also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of human cancer or neoplastic disease. BullFrog AI Holdings, Inc. was founded in 2017 and is based in Gaithersburg, Maryland.